The New Progress in Cancer Treatment
34,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
17 °P sammeln
  • Broschiertes Buch

In the half century after the Second World War, oncology has developed greatly both in the world and in China. There are three traditional major treatments: surgery, which has been used to treat tumors for more than a hundred years; radiotherapy, which has been used for ninety years; and chemotherapy, which has been used for nearly seventy years. In the 1980s, there was the rise of biological therapy and immunotherapy. The effects of oncological therapy have made a lot of progress. Many tumors have achieved good results, but there are still many solid tumors whose efficacy are still very poor.…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
In the half century after the Second World War, oncology has developed greatly both in the world and in China. There are three traditional major treatments: surgery, which has been used to treat tumors for more than a hundred years; radiotherapy, which has been used for ninety years; and chemotherapy, which has been used for nearly seventy years. In the 1980s, there was the rise of biological therapy and immunotherapy. The effects of oncological therapy have made a lot of progress. Many tumors have achieved good results, but there are still many solid tumors whose efficacy are still very poor. In 1985, the author followed up more than three thousand patients who had undergone the general surgical operation and thorax surgical operation. The results showed that most patients relapsed and metastasized within two to three years after surgery. Some patients even relapsed in a few months. This made me deeply realize that surgery is successful and standardized, but the long-term effect is not satisfied or that the long-term treatment is a failure.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Xu Ze, male, was born in Leping County, Jiangxi Province, on October 1933. He graduated from Tongji Medical University in 1956 and successively held the posts of director of department of surgery of Affiliated Hospital of Hubei College of Traditional Chinese Medicine, professor, chief physician, tutor of postgraduate and doctoral students, president of Experimental Surgery Restitute Institute of Hubei College of Traditional Chinese Medicine, director of Abdominal Tumor Surgery Research Room, and Director of Anti-Carcinomatous Metastasis and Reoccurrence Research Room. In addition, he held concurrent posts of standing director of China Medical Association Wuhan Branch, vice president of Wuhan Micro-Circulation Academy, academic member of International Liver Disease Research, Cooperation and Exchange Center, member of International Surgeon Union, standing member of first, second, third, and fourth editorial board of China Experimental Surgery Journal, standing member of first, second, and third editorial board of Abdominal Surgery Journal. He is enjoying Special Allowance of State Council. He has been engaged in surgery work for forty-nine years and accumulated rich experience in radical operation of lung cancer, esophageal carcinoma, liver cancer, carcinoma of gallbladder, adenocarcinoma of pancreas, gastric carcinoma, and intestinal cancer, as well as in clinical therapy with Chinese traditional medicine combined with Western medicine of prevention of reoccurrence and metastasis after operation. Xu Jie, male, graduated from Hubei College of Traditional Chinese Medicine in 1992. He graduated from the Department of Clinical Medicine in Hubei Medical University in 1996. Now he is chief physician in Hubei University of Traditional Chinese Medicine Hospital and Hubei Provincial Hospital of Surgery. He is engaged in experimental surgical tumor research, general surgery, and urology clinical work. Bin Wu, MD, PhD, graduated from College of Yunyang of Tongji University of Medical Sciences for her MD degree. She studied her masters degree and her PhD in Sun Yat-Sen University of Medical Sciences. After she received her PhD, she worked as a postdoctoral fellow in the John Hopkins Medical School and University of Maryland Medical School. She passed all of her USMLE tests and is going to do her residency training in America. She dedicates herself to oncology clinical and research. Her goal is to conquer cancer, which she believes is great contribution to our health. She has an only daughter, named Lily Xu who is Dr. Bin Wus great assistant for many of the critical and challenging thinking of the medical topics and for the advanced technology such as the computer, etc.